File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1371/journal.ppat.1008583
- Scopus: eid_2-s2.0-85091620452
- PMID: 32970783
- WOS: WOS:000576176800002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine
Title | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
---|---|
Authors | |
Editors | Editor(s):Hobman, TC |
Keywords | clinical trial (topic) human immunology influenza Influenza A virus |
Issue Date | 2020 |
Publisher | Public Library of Science. The Journal's web site is located at http://pathogens.plosjournals.org/perlserv/?request=index-html&issn=1553-7374 |
Citation | PLoS Pathogens, 2020, v. 16 n. 9, p. article no. e1008583 How to Cite? |
Abstract | The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important downstream questions about global deployment of a universal influenza vaccine that should be explored to minimize unintended consequences and maximize benefits. Here, we review and synthesize the questions most relevant to predicting the population benefits of universal influenza vaccines and discuss how existing information could be mined to begin to address these questions. We review three research topics where computational modeling could bring valuable evidence: immune imprinting, viral evolution, and transmission. We address the positive and negative consequences of imprinting, in which early childhood exposure to influenza shapes and limits immune responses to future infections via memory of conserved influenza antigens. However, the mechanisms at play, their effectiveness, breadth of protection, and the ability to “reprogram” already imprinted individuals, remains heavily debated. We describe instances of rapid influenza evolution that illustrate the plasticity of the influenza virus in the face of drug pressure and discuss how novel vaccines could introduce new selective pressures on the evolution of the virus. We examine the possible unintended consequences of broadly protective (but infection-permissive) vaccines on the dynamics of epidemic and pandemic influenza, compared to conventional vaccines that have been shown to provide herd immunity benefits. In conclusion, computational modeling offers a valuable tool to anticipate the benefits of ambitious universal influenza vaccine programs, while balancing the risks from endemic influenza strains and unpredictable pandemic viruses. Moving forward, it will be important to mine the vast amount of data generated in clinical studies of universal influenza vaccines to ensure that the benefits and consequences of these vaccine programs have been carefully modeled and explored. |
Persistent Identifier | http://hdl.handle.net/10722/290484 |
ISSN | 2023 Impact Factor: 5.5 2023 SCImago Journal Rankings: 2.223 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Viboud, C | - |
dc.contributor.author | Gostic, K | - |
dc.contributor.author | Nelson, MI | - |
dc.contributor.author | Price, GE | - |
dc.contributor.author | Perofsky, A | - |
dc.contributor.author | Sun, K | - |
dc.contributor.author | Sequeira Trovão, N | - |
dc.contributor.author | Cowling, BJ | - |
dc.contributor.author | Epstein, SL | - |
dc.contributor.author | Spiro, DJ | - |
dc.contributor.editor | Hobman, TC | - |
dc.date.accessioned | 2020-11-02T05:42:53Z | - |
dc.date.available | 2020-11-02T05:42:53Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | PLoS Pathogens, 2020, v. 16 n. 9, p. article no. e1008583 | - |
dc.identifier.issn | 1553-7366 | - |
dc.identifier.uri | http://hdl.handle.net/10722/290484 | - |
dc.description.abstract | The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important downstream questions about global deployment of a universal influenza vaccine that should be explored to minimize unintended consequences and maximize benefits. Here, we review and synthesize the questions most relevant to predicting the population benefits of universal influenza vaccines and discuss how existing information could be mined to begin to address these questions. We review three research topics where computational modeling could bring valuable evidence: immune imprinting, viral evolution, and transmission. We address the positive and negative consequences of imprinting, in which early childhood exposure to influenza shapes and limits immune responses to future infections via memory of conserved influenza antigens. However, the mechanisms at play, their effectiveness, breadth of protection, and the ability to “reprogram” already imprinted individuals, remains heavily debated. We describe instances of rapid influenza evolution that illustrate the plasticity of the influenza virus in the face of drug pressure and discuss how novel vaccines could introduce new selective pressures on the evolution of the virus. We examine the possible unintended consequences of broadly protective (but infection-permissive) vaccines on the dynamics of epidemic and pandemic influenza, compared to conventional vaccines that have been shown to provide herd immunity benefits. In conclusion, computational modeling offers a valuable tool to anticipate the benefits of ambitious universal influenza vaccine programs, while balancing the risks from endemic influenza strains and unpredictable pandemic viruses. Moving forward, it will be important to mine the vast amount of data generated in clinical studies of universal influenza vaccines to ensure that the benefits and consequences of these vaccine programs have been carefully modeled and explored. | - |
dc.language | eng | - |
dc.publisher | Public Library of Science. The Journal's web site is located at http://pathogens.plosjournals.org/perlserv/?request=index-html&issn=1553-7374 | - |
dc.relation.ispartof | PLoS Pathogens | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | clinical trial (topic) | - |
dc.subject | human | - |
dc.subject | immunology | - |
dc.subject | influenza | - |
dc.subject | Influenza A virus | - |
dc.title | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine | - |
dc.type | Article | - |
dc.identifier.email | Cowling, BJ: bcowling@hku.hk | - |
dc.identifier.authority | Cowling, BJ=rp01326 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1371/journal.ppat.1008583 | - |
dc.identifier.pmid | 32970783 | - |
dc.identifier.pmcid | PMC7514029 | - |
dc.identifier.scopus | eid_2-s2.0-85091620452 | - |
dc.identifier.hkuros | 318569 | - |
dc.identifier.volume | 16 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | article no. e1008583 | - |
dc.identifier.epage | article no. e1008583 | - |
dc.identifier.isi | WOS:000576176800002 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1553-7366 | - |